🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4396 Illinois 2477 Georgia 2346 Arizona 2230
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5299 Florida4396 Illinois2477 Georgia2346 Arizona2230
All 51 states
Target enrolment
to

Trials with a site in Georgia

2346 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
Boehringer Ingelheim
Phase 3
4,200
California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana
2025-05-20
Recruiting
Pelacarsen Roll-over Extension Program
NCT06875973Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
599
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-05-19
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)
NCT06747117Lower Extremity Acute Limb Ischemia, LE ALI
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Recruiting
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729Acute Treatment of Migraine
Pfizer
Phase 1
16
Arkansas, District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Oklahoma
2025-05-16
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426Central Line Associated Blood Stream Infections (CLABSI)
CorMedix Therapeutics
Phase 3
200
California, District of Columbia, Florida, Georgia, Illinois, Iowa, Maryland, Minnesota
2025-05-14
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, Florida, Georgia, Massachusetts, Minnesota, Missouri, Pennsylvania, Texas
2025-05-14
Recruiting
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425Atopic Dermatitis
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Active, closed
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509Coronary Artery Disease
Philips Clinical & Medical Affairs Global
Not applicable
824
Colorado, Georgia, New York
2025-05-14
Recruiting
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968Schizophrenia
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
425
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Active, closed
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079Osteoarthritis (OA) of the Knee
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034Schizophrenia
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Active, closed
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, Inc.
Phase 1/2
12
California, Georgia, Maryland, Massachusetts, Utah
2025-05-08
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660Cervical Cancer
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Active, closed
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
NCT06939283Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Arizona, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-05-06
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
Phase 2
164
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Active, closed
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity
Hoffmann-La Roche
Phase 2
285
Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio
2025-05-05
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Not yet open
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
NCT06919796Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
PharmaJet, Inc.
Phase 2
40
Georgia
2025-05-01
Recruiting
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
NCT06942949Kidney Calculi; Ureteral Calculi
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320Generalized Anxiety Disorder (GAD)
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085Lymphoma
Hoffmann-La Roche
Phase 1
50
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maryland, New Mexico
2025-04-28
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177Cancer Weight Loss
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Active, closed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836Alzheimer Disease
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kansas
2025-04-24
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930Lupus Erythematosus, Systemic
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Florida, Georgia, Kansas, Maryland, Minnesota
2025-04-17
Recruiting
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214New Onset Generalized Myasthenia Gravis (gMG)
argenx
Phase 4
30
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Active, closed
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
NCT06907511Pandemic Influenza Immunization, Healthy Volunteers
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Active, closed
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065MASH
Hoffmann-La Roche
Phase 1
50
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
Active, closed
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
NCT06891066Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
NCT06893588Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Vesalio
Observational
200
California, Connecticut, Florida, Georgia, Illinois, Iowa, Kentucky, Maine
2025-04-14
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
250
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-04-09
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
869
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Active, closed
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
NCT06973720Obesity, Overweight or Obesity
Pfizer
Phase 2
268
Florida, Georgia, New Jersey
2025-04-07
Active, closed
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264HEPATITIS C VIRUS CHRONIC INFECTION
Atea Pharmaceuticals, Inc.
Phase 3
880
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-04-07
Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
NCT05766839Hyperkalemia
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Active, closed
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050Graft-versus-host Disease (GVHD)
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Florida, Georgia, Texas
2025-04-02
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144Metastatic Solid Tumor, Advanced Solid Tumor
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Active, closed
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463Celiac Disease
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112Major Depressive Disorder
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Active, closed
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
Phase 1
135
California, Connecticut, Georgia, New Jersey
2025-03-28
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
By invitation
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
NCT07224555Hair Thinning
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
60
Florida, Georgia, Maryland, Washington
2025-03-27
Recruiting
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328Ulcerative Colitis, Crohn's Disease
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Active, closed
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427Aortic Stenosis Symptomatic
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Recruiting
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
NCT06749054HIV-1-infection
Gilead Sciences
Phase 2
12
Georgia
2025-03-26
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Recruiting
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT06911424Bacterial Conjunctivitis
Baxis Pharmaceuticals, Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Idaho, Illinois, Maryland, Nevada
2025-03-21
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942Psoriasis, Overweight or Obesity
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
By invitation
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110Major Depressive Disorder
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
Hoffmann-La Roche
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
NCT06495424Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Rows per page Showing 701–800 of 2346
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=8

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,346 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,211 of the 2,346 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,035 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.